LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston

PASADENA, CA, May 08, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.

This workshop will bring together leading experts from the pharmaceutical industry and academia to discuss a radically different approach to cancer therapy that is being spearheaded by LIXTE’s research team at the Netherlands Cancer Institute. This unconventional approach is based on the deliberate over-activation of oncogenic signaling in cancer cells as a therapeutic strategy using LIXTE’s lead compound, LB-100.

LIXTE is the only company that has a drug in clinical trials with demonstrated capacity to over-activate oncogenic signaling. The results obtained with LB-100 were recently posted online in a paper titled “Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy” in the scientific journal Cancer Discovery, which will be published in the journal’s July 2024 issue. This study showed that LB-100 triggers hyper-activation of the signals that are responsible for the deregulated proliferation of cancer cells, thus leading to cell death. This approach is the opposite of most of the current generation of cancer therapies and opens potentially new treatment strategies. LIXTE currently has three ongoing clinical trials utilizing LB-100 to enhance various cancer therapies.

Professor René Bernards, Ph.D., of the Netherlands Cancer Institute (NKI), a leader in the field of molecular carcinogenesis and a member of LIXTE’s Board of Directors, is co-leading the workshop. The NKI presentation will focus on findings of a recent pre-clinical study showing that LIXTE’s lead compound, LB-100, can force cancer cells to give up their cancer-causing properties.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm.

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress.